mecasermin (Increlex, Insmed, recombinant IGF1)

Introduction

Tradenames: Increlex, FDA approved 2005

Indications

• long-term treatment of growth failure in children with severe primary IGF1 deficiency

Contraindications

• not a substitute for growth hormone treatment in patients with growth hormone deficiency

Dosage

• 40 to 80 ug/kg SQ BID

Injection: 10 mg/mL, multiple dose glass vials (40 mg/vial)

Mechanism of action

• contains human insulin-like growth factor-1 (rhIGF-1) produced by recombinant DNA technology Manufacturers: iPlex, Insmed

More general terms

• endocrine agent
• insulin-like growth factor-1